A cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP of the European Pharmacopoeia monograph is often referred to as a cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid Certificate of Suitability (COS). The purpose of a cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid to their clients by showing that a cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP has been issued for it. The manufacturer submits a cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP (COS) as part of the market authorization procedure, and it takes on the role of a cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP holder for the record. Additionally, the data presented in the cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid DMF.
A cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid suppliers with CEP (COS) on PharmaCompass.